Compare THH & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THH | NCEL |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | Japan | Switzerland |
| Employees | 116 | 4 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 22.0M |
| IPO Year | N/A | N/A |
| Metric | THH | NCEL |
|---|---|---|
| Price | $0.21 | $3.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 124.8K | 33.2K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $305.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $1.83 |
| 52 Week High | $56.26 | $5.12 |
| Indicator | THH | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 27.51 | 46.33 |
| Support Level | N/A | $2.58 |
| Resistance Level | $0.53 | $3.70 |
| Average True Range (ATR) | 0.02 | 0.34 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 4.47 | 0.00 |
Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.